Decentralized clinical trials (DCTs) recently gained attention in research necessary for drug development. While the COVID-19 pandemic proved to be a challenging time in this arena, drug development was a critical area of emphasis in the rapid development of vaccines. DCTs were necessary to allow research activities to occur across many locations. Although the use of DCTs play a pivotal role in reshaping healthcare, as technology expands further into the digital space implementation challenges must be considered. A working group of experts assembled, during an interactive learning exercise at the Conv2X conference (2023), to explore challenges related to the diffusion of innovation among key stakeholders. Common “pain points” of technology and an innovative approach that used a blockchain anchored solution were presented. Experts were divided into three stakeholder groups (patients, payers, and pharmaceutical sponsor) which reconvened for an overall discussion. Several themes, that can be supported by blockchain technology, emerged. These include enhanced efficiencies, patient experience / demographic diversity, data integrity / privacy / security, and cost-effectiveness. Future research may focus on additional stakeholder groups that are less familiar with these technological advances and using technology to increase diversity in study populations.

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.